Fenwick Represents Star Therapeutics in Oversubscribed $125M Series D Funding

Fenwick represented Star Therapeutics, a clinical stage biotechnology company, in its $125 million Oversubscribed Series D funding. The round was co-led by Sanofi Ventures and Viking Global Investors with participation from Janus Henderson Investors, Frazier Life Sciences, GordonMD Global Investments, Agent Capital, Blue Owl Capital, Catalio Capital Management, Cormorant Asset management, New Leaf Ventures Partners, NYBC Ventures, OrbiMed, Qatar Investment Authority (QIA), RA Capital management, Redmile Group, Sofinnova Investments, Soleus Capital, and Westlake BioPartners.

Star Therapeutics will use the funds to support the continued advancement of its pipeline including its lead program, VGA039. Additional information can be obtained here.

The Fenwick transaction team was led by corporate partner Matt Rossiter and included associates James Li, Olga Terets, Bradley Shepard, Sydney Everett.